Statseal® for Central Venous Catheter Insertion Sites in Critical Care

NAActive, not recruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

October 14, 2024

Primary Completion Date

September 19, 2025

Study Completion Date

November 30, 2025

Conditions
Central LineCentral Venous CatheterVascular AccessCritical CareHemostatic
Interventions
OTHER

A haemostatic mineral powder product.

The intervention is the addition of an approved and commercially available haemostatic powder product which is indicated for the temporary external control of bleeding. Recommended application is at central venous catheter insertion, prior to the site being covered with a transparent dressing. Comprising a hydrophilic polymer and potassium ferrate, once in contact with protein-rich body fluids, the mechanism of action of the powder is to dehydrate and to absorb exudate. This simultaneously forms a low pH seal barrier which is hostile to microbial penetration while also purporting to help maintain clean and dry environment beneath transparent site dressings.

Trial Locations (1)

L14 3PE

Liverpool Heart and Chest Hospital NHS FoundationTrust, Liverpool

All Listed Sponsors
collaborator

Biolife LLC

UNKNOWN

lead

Liverpool Heart and Chest Hospital NHS Foundation Trust

OTHER

NCT06451185 - Statseal® for Central Venous Catheter Insertion Sites in Critical Care | Biotech Hunter | Biotech Hunter